Last reviewed 01/2018

Docetaxel is a taxoid which is indicated for the treatment of:

  • ovarian cancer resistant to platinum-based chemotherapy
  • prostate cancer - is recommended, within its licensed indications, as a treatment option for men with hormone-refractory metastatic prostate cancer only if their Karnofsky performance-status score is 60% or more (1)
  • breast cancer resistant to first line treatment such as anthracyline
    • docetaxel (given with doxorubicin and cyclophosphamide) is recommended as a possible adjuvant treatment for women with early node-positive breast cancer (2)


  1. NICE (June 2006). Docetaxel for the treatment of hormone-refractory metastatic prostate cancer.
  2. NICE (September 2006). Docetaxel for the adjuvant treatment of early node-positive breast cancer